{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:17:36Z","timestamp":1783387056915,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UVA2013-5842"],"award-info":[{"award-number":["UVA2013-5842"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T12:39:44Z","timestamp":1542976784000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-6893","authenticated-orcid":false,"given":"Tara M.","family":"Mackay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice N.","family":"van Erning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-5520","authenticated-orcid":false,"given":"Lydia G.M.","family":"van der Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Haj Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery E.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2018.10.008_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00432-016-2140-5","article-title":"Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in The Netherlands","volume":"142","author":"Haj Mohammad","year":"2016","journal-title":"J Canc Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.10.008_bib2","first-page":"70","article-title":"Treatment of metastatic pancreatic adenocarcinoma: a review","volume":"28","author":"Thota","year":"2014","journal-title":"Oncology (Williston Park, NY)"},{"issue":"19","key":"10.1016\/j.ejca.2018.10.008_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2018.10.008_bib4","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2018.10.008_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.10.008_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MPA.0b013e3181bd6489","article-title":"Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States","volume":"39","author":"Lau","year":"2010","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.ejca.2018.10.008_bib7","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1002\/bjs.10772","article-title":"Defining the molecular pathology of pancreatic body and tail adenocarcinoma","volume":"105","author":"Dreyer","year":"2018","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.ejca.2018.10.008_bib8","first-page":"371","article-title":"The anatomic location of pancreatic cancer is a prognostic factor for survival","volume":"10","author":"Artinyan","year":"2008","journal-title":"HPB Offic J Int HPB Assoc"},{"issue":"2","key":"10.1016\/j.ejca.2018.10.008_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00006676-200403000-00007","article-title":"Onset symptoms and tumour locations as prognostic factors of pancreatic cancer","volume":"28","author":"Watanabe","year":"2004","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.ejca.2018.10.008_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00000658-199605000-00006","article-title":"Management of adenocarcinoma of the body and tail of the pancreas","volume":"223","author":"Brennan","year":"1996","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2018.10.008_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12893-015-0110-5","article-title":"The prognostic influence of intrapancreatic tumour location on survival after resection of pancreatic ductal adenocarcinoma","volume":"15","author":"Ruess","year":"2015","journal-title":"BMC Surg"},{"issue":"1","key":"10.1016\/j.ejca.2018.10.008_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1072-7515(99)00075-7","article-title":"Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database","volume":"189","author":"Sener","year":"1999","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.ejca.2018.10.008_bib13","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","article-title":"Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and End Results database analysis","volume":"23","author":"Oweira","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.ejca.2018.10.008_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2018.10.008_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MPA.0b013e3182021376","article-title":"Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma","volume":"40","author":"Morizane","year":"2011","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.ejca.2018.10.008_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MPA.0b013e3181e21b1b","article-title":"Prognostic factors for survival in patients with unresectable pancreatic cancer","volume":"39","author":"Weber","year":"2010","journal-title":"Pancreas"},{"issue":"3\u20134","key":"10.1016\/j.ejca.2018.10.008_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000328449","article-title":"A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer","volume":"80","author":"Yi","year":"2011","journal-title":"Oncology"},{"issue":"25","key":"10.1016\/j.ejca.2018.10.008_bib18","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1097\/MD.0000000000001012","article-title":"Initial metastatic site as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ejca.2018.10.008_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.amjsurg.2018.01.037","article-title":"The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer","volume":"216","author":"Hong","year":"2018","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.ejca.2018.10.008_bib20","first-page":"358","article-title":"Radical surgery of oligometastatic pancreatic cancer","volume":"43","author":"Hackert","year":"2017","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.10.008_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11605-011-1765-6","article-title":"Pancreatic adenocarcinoma: complete tumour extirpation improves survival benefit despite larger tumours for patients who undergo distal pancreatectomy and splenectomy","volume":"16","author":"Toomey","year":"2012","journal-title":"J Gastrointest Surg Offic J Soc Surg Aliment Tract"},{"issue":"6","key":"10.1016\/j.ejca.2018.10.008_bib22","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2018.10.008_bib23","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.008_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2016.11.026","article-title":"Underestimation of pancreatic cancer in the national cancer registry - reconsidering the incidence and survival rates","volume":"72","author":"Fest","year":"2017","journal-title":"Eur J cancer (Oxford, England: 1990)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T14:26:18Z","timestamp":1544797578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918314369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"alternative-id":["S0959804918314369"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.10.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}